AIMS: Skeletal myoblasts are used in repair of ischaemic myocardium. However, a large fraction of grafted myoblasts degenerate upon engraftment. Colony-stimulating factor-1 (CSF-1) accelerates myoblast proliferation and angiogenesis. We hypothesized that CSF-1 overexpression improves myoblast survival and cardiac function in ischaemia-induced heart failure. METHODS AND RESULTS: Three weeks following myocardial infarction, rats developed heart failure and received intramyocardial injections of mouse CSF-1-transfected or untransfected primary autologous rat myoblasts, recombinant human CSF-1, mouse CSF-1 expressing plasmids, or culture medium. Tissue gene and protein expression was measured by quantitative RT-PCR (reverse transcription-polymerase chain reaction) and western blotting. Fluorescence imaging and immunocytochemistry were used to analyse myoblasts, endothelial cells, macrophages, and infarct wall thickening. Electrocardiograms were recorded online using a telemetry system. Left ventricular function was assessed by echocardiography over time, and improved significantly only in the CSF-1-overexpressing myoblast group. CSF-1-overexpression enhanced myoblast numbers and was associated with an increased infarct wall thickness, enhanced angiogenesis, increased macrophage recruitment and upregulated matrix metalloproteases (MMP)-2 and -12 in the zone bordering the infarction. Transplantation of CSF-1-overexpressing myoblasts did not result in major arrhythmias. CONCLUSION: Autologous intramyocardial transplantation of CSF-1 overexpressing myoblasts might be a novel strategy in the treatment of ischaemia-induced heart failure.
AIMS: Skeletal myoblasts are used in repair of ischaemic myocardium. However, a large fraction of grafted myoblasts degenerate upon engraftment. Colony-stimulating factor-1 (CSF-1) accelerates myoblast proliferation and angiogenesis. We hypothesized that CSF-1 overexpression improves myoblast survival and cardiac function in ischaemia-induced heart failure. METHODS AND RESULTS: Three weeks following myocardial infarction, rats developed heart failure and received intramyocardial injections of mouseCSF-1-transfected or untransfected primary autologous rat myoblasts, recombinant humanCSF-1, mouseCSF-1 expressing plasmids, or culture medium. Tissue gene and protein expression was measured by quantitative RT-PCR (reverse transcription-polymerase chain reaction) and western blotting. Fluorescence imaging and immunocytochemistry were used to analyse myoblasts, endothelial cells, macrophages, and infarct wall thickening. Electrocardiograms were recorded online using a telemetry system. Left ventricular function was assessed by echocardiography over time, and improved significantly only in the CSF-1-overexpressing myoblast group. CSF-1-overexpression enhanced myoblast numbers and was associated with an increased infarct wall thickness, enhanced angiogenesis, increased macrophage recruitment and upregulated matrix metalloproteases (MMP)-2 and -12 in the zone bordering the infarction. Transplantation of CSF-1-overexpressing myoblasts did not result in major arrhythmias. CONCLUSION: Autologous intramyocardial transplantation of CSF-1 overexpressing myoblasts might be a novel strategy in the treatment of ischaemia-induced heart failure.
Authors: D Abraham; R Hofbauer; R Schäfer; R Blumer; P Paulus; A Miksovsky; H Traxler; A Kocher; S Aharinejad Journal: Circ Res Date: 2000-10-13 Impact factor: 17.367
Authors: Rutger J Hassink; Aart Brutel de la Rivière; Christine L Mummery; Pieter A Doevendans Journal: J Am Coll Cardiol Date: 2003-03-05 Impact factor: 24.094
Authors: M Jain; H DerSimonian; D A Brenner; S Ngoy; P Teller; A S Edge; A Zawadzka; K Wetzel; D B Sawyer; W S Colucci; C S Apstein; R Liao Journal: Circulation Date: 2001-04-10 Impact factor: 29.690
Authors: B Pouzet; S Ghostine; J T Vilquin; I Garcin; M Scorsin; A A Hagège; D Duboc; K Schwartz; P Menasché Journal: Circulation Date: 2001-09-18 Impact factor: 29.690
Authors: P Menasché; A A Hagège; M Scorsin; B Pouzet; M Desnos; D Duboc; K Schwartz; J T Vilquin; J P Marolleau Journal: Lancet Date: 2001-01-27 Impact factor: 79.321
Authors: B Pouzet; J T Vilquin; A A Hagège; M Scorsin; E Messas; M Fiszman; K Schwartz; P Menasché Journal: Circulation Date: 2000-11-07 Impact factor: 29.690
Authors: Seyedhossein Aharinejad; Dietmar Abraham; Patrick Paulus; Hojatollah Abri; Michael Hofmann; Karl Grossschmidt; Romana Schäfer; E Richard Stanley; Reinhold Hofbauer Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701
Authors: Ana Maria Gómez; Beat Schwaller; Hartmut Porzig; Guy Vassort; Ernst Niggli; Marcel Egger Journal: Circ Res Date: 2002-08-23 Impact factor: 17.367
Authors: Julia Menke; Yasunori Iwata; Whitney A Rabacal; Ranu Basu; E Richard Stanley; Vicki R Kelley Journal: J Am Soc Nephrol Date: 2011-09-01 Impact factor: 10.121
Authors: Julia Menke; Jörg Kriegsmann; Carl Christoph Schimanski; Melvin M Schwartz; Andreas Schwarting; Vicki R Kelley Journal: Cancer Res Date: 2011-11-03 Impact factor: 12.701
Authors: Vasileios Karantalis; Wayne Balkan; Ivonne H Schulman; Konstantinos E Hatzistergos; Joshua M Hare Journal: Am J Physiol Heart Circ Physiol Date: 2012-05-25 Impact factor: 4.733
Authors: Julia Menke; Yasunori Iwata; Whitney A Rabacal; Ranu Basu; Yee G Yeung; Benjamin D Humphreys; Takashi Wada; Andreas Schwarting; E Richard Stanley; Vicki R Kelley Journal: J Clin Invest Date: 2009-07-01 Impact factor: 14.808